Amara Okafor

Amara Okafor leads research at Halvren Therapeutics, where her teams design programmable mRNA medicines from target selection through to first-in-human studies. Before Halvren, Amara spent a decade in academic RNA biology and co-founded two platform companies.

Amara opens Montanara with a look at where programmable medicines will be in ten years, and what has to change to get there.